Zhongguancun Science City International Medical Valley Breaks Ground, Pioneering Smart-Medical Integration

VCBeat has learned that construction on the Zhongguancun Science City International Medical Valley project officially commenced on December 19, 2024.

ZGC Science City International Medical Valley Project is located in Block HD00-0205, northeast of Shangzhuang Town, Haidian District. The total planned land area is approximately 95.3 hectares, with a total building scale of about 807,000 square meters. The project integrates multifunctional spaces including R&D offices, pilot production facilities, public technical service platforms, CDMO technical service platforms, clinical research hospitals, commercial amenities, and talent apartments, committed to realizing the development concept of industry-city integration.

From the perspective of its development model, the MedValley project will implement the concept of “whole-industry-chain collaboration”: attracting top-tier R&D institutions and enterprises upstream to gather sources of innovation; providing public technical service platforms midstream to lower R&D barriers and facilitate the implementation of innovative ideas; and establishing a technology transfer zone downstream to accelerate the industrialization of innovative achievements.

In fact, the Zhongguancun Science City International Medical Valley project has established a complete industrial chain encompassing incubation, R&D, small-scale trials, pilot-scale trials, and production, thereby ensuring supply chain integrity. This comprehensive framework enhances corporate competitiveness and synergies. In the future, the project will foster a high degree of clustering among pharmaceutical and health-related enterprises, facilitating resource sharing, technological exchange, and innovative collaboration, while generating synergistic effects across upstream and downstream segments of the industrial chain.

Meanwhile, leveraging the concentration of universities and research institutes in Haidian District, and with the continuous improvement and refinement of industry-academia-research collaboration mechanisms, the park’s innovation capacity and efficiency in technology transfer will steadily increase, while providing ample talent support to enterprises. The project also plans to establish joint innovation platforms with universities and research institutions, deepen industry-academia-research cooperation, build a vibrant innovation ecosystem network, ensure the project’s long-term competitiveness, and promote the sustainable development of the pharmaceutical and healthcare industry.

On the other hand, the improvement of policies and supporting infrastructure will also serve as a strong boost to the Medical Valley project. The Zhongguancun Science City International Medical Valley project enjoys policy support from Haidian District, and will subsequently establish an investment fund with the local government to attract more high-quality enterprises to settle in.

The Zhongguancun Science City International Medical Valley project features planned public technical service platforms and government service halls to provide enterprises with technical support, innovation services, and administrative assistance. The park’s power supply adopts a dual-circuit system with a load capacity of 150W/㎡; space is reserved for integrated sewage treatment modules; the energy center provides centralized heating and cooling sources, with individual units pre-equipped with interfaces and necessary conditions; industrial steam and other utilities are also supplied. These facilities directly impact the operational efficiency and costs of enterprises.

In addition, the Zhongguancun Science City International Medical Valley project is operated and managed by Haixing Technology, a subsidiary of Haixin Yu Urban Renewal Group. With extensive experience in park management and an excellent team, it provides superior services to tenant enterprises.

The Zhongguancun Science City International Medical Valley project is expected to be completed by the end of 2027.

In terms of industrial layout, the Zhongguancun Science City International Medical Valley project focuses on three major sectors: “innovative drugs, high-end medical devices, and smart healthcare.” It covers the entire industry chain from “incubation, small-scale trials, pilot-scale trials, to production,” striving to become a pioneer zone for the integration of intelligence and medicine. The project actively undertakes the transformation of innovative achievements in biopharmaceuticals across China and provides high-quality pilot production space and infrastructure for leading enterprises. With seven common technology platforms as key instruments, the park establishes an industrial development and service system, building Beijing’s leading source for pharmaceutical and health innovation, thereby forming the “1237” industrial positioning.

Guided by the “Four Orientations” and focusing on global scientific frontiers and life health, we will integrate Beijing’s resource advantages in the pharmaceutical and health industries to attract leading global talent. We aim to build a comprehensive industrial park featuring full-function and full-factor capabilities spanning concept validation, incubation, pilot-scale testing, registration, and industrialization, thereby attracting renowned global enterprises and high-quality projects to establish their presence and thrive within the park.

Category I: Revenue from Industrial Space Services

First, generate basic operating revenue by leasing industrial space; second, capture service premiums by providing shared professional services and lifestyle amenities; third, adhere to the principle that “no investment, no wealth,” leveraging government- and group-affiliated industrial funds to combine early-stage and small-scale investments with strategic investments for investment returns.

Category 2: Economic Benefits of Industrial Cluster Development

First, retain high-quality incubated projects in the pharmaceutical and healthcare sectors within Haidian District to generate various economic benefits; second, drive industrial development in the relevant plots of Shangzhuang; third, by establishing a nationally influential innovation hub for pharmaceuticals and healthcare, coordinate with related pharmaceutical and healthcare parks in Beijing to promote the development of Beijing’s pharmaceutical and healthcare industry, helping Beijing become the world’s most influential cluster for the biopharmaceutical industry.

Innovative Drugs:Cell and gene therapy, antibodies, recombinant proteins, novel vaccines, nucleic acid drugs, etc.

High-End Medical Devices:Imaging equipment, pharmaceutical robots, high-end implantable consumables, in vitro diagnostics, brain-computer interfaces, etc.

Future Frontiers:AI-empowered upgrades and modernization of medical devices, ADC products, small nucleic acid products (classified as gene and cell therapies but delivered as chemical drugs), cell therapies, gene therapies, and various genetic modification approaches such as genetic engineering and gene editing.

Protein R&D and Production Platform:Leveraging ZhiDao Bio’s Strategic Layout to Build a Recombinant Protein Industry Platform and Drive the Development of the Recombinant Protein Sector

CGT Manufacturing Platform:Yimiao Bio Establishes a Fully Localized End-to-End Cell Therapy Manufacturing Platform to Drive the Development of the CGT Industry

Green Chemical Synthesis Platform for Small-Molecule Drugs: Huaguan Bio’s Green R&D and Production Platform for Small-Molecule APIs Based on Enzymatic Continuous-Flow Reactions

Drug Delivery Industry Platform:Yinno Pharmaceuticals Builds Next-Generation Active Targeting Liposomal Drug Delivery Technology

Recombinant Protein R&D and Manufacturing Platform for Veterinary Biologics:Weijie Xin Recombinant Protein Animal Health Drug R&D and Production Platform

High-End Medical Device CDMO Platform:Building a High-End Medical Device CDMO Platform Centered on Shuimu Dongfang’s Surgical Robot Technology

AI Drug Discovery Platform:Building an AI Drug Discovery Platform with BioMap’s Globally Leading AI Technology

The commencement of construction for the Zhongguancun Science City International Medical Valley project marks a significant opportunity for the integration and upgrading of the pharmaceutical and health industries in the northern area of Zhongguancun Science City, while also representing an active exploration and practice of an innovative development model that integrates intelligence with healthcare. In the future, Zhongguancun Science City International Medical Valley will fully leverage its regional advantages, pool resources from all sectors, and harness the leading role of technological innovation to become a pacesetter in the pharmaceutical and health industry. By pursuing high-end, differentiated, and distinctive development, it aims to emerge as a new growth pole for Haidian District and contribute to the high-quality economic development of the entire city.

Under the leadership of Haiguotou Group, Beijing Haixinyu Urban Renewal Group Co., Ltd. will efficiently advance project construction. Through targeted investment promotion and policy guidance, it aims to attract and cultivate a cohort of leading enterprises with core competitiveness. By continuously strengthening the park’s innovation service system and enhancing industrial service capabilities, the company is committed to establishing Zhongguancun Science City International Medical Valley as a premier showcase of China’s pharmaceutical and health industry.

The investment promotion focus of the International Medical Valley in Zhongguancun Science City includes innovative drugs (such as cell and gene therapies, antibodies, recombinant proteins, novel vaccines, and nucleic acid drugs), high-end medical devices (such as imaging equipment, medical robots, high-end implantable consumables, in vitro diagnostics, and brain-computer interfaces), and future frontier technologies (such as AI-enabled upgrades of medical equipment and new drug development, antibody-drug conjugates [ADCs], small nucleic acid products, stem cell therapy, organ-on-a-chip, and gene editing).